Epothilones in breast cancer: current status and future directions

References

• Gueritte-Voegelein F, Guenard D, Lavelle F et al. Relationships between the structure of taxol analogues and their antimitotic activity. J. Med. Chem.34(3), 992–998 (1991).
   PubMed Web of Science ®Google Scholar
• Szakacs G, Paterson JK, Ludwig JA et al. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov.5, 219–234 (2006).
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Kamath K, Vanier-Viornery A et al. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br. J. Cancer88, 1793–1799 (2003).
   PubMed Web of Science ®Google Scholar
• Maney T, Wagenbach M, Wordeman L. Molecular dissection of the microtubule depolymerizing activity of mitotic centromere-associated kinesin. J. Biol. Chem.276, 34753–34758 (2001).
   PubMed Web of Science ®Google Scholar
• Bonnet C, Boucher D, Lazereg S et al. Differential binding regulation of microtubule associated proteins MAP1A, MAP1B, and MAP2 by tubulin polyglutamylation. J. Biol. Chem.276, 12839–12848 (2001).
   PubMed Web of Science ®Google Scholar
• Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol.17, 1061–1070 (1999).
   PubMed Web of Science ®Google Scholar
• Kavallaris M, Tait AS, Walsh BJ et al. Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells. Cancer Res.61, 5803–5809 (2001).
   PubMed Web of Science ®Google Scholar
• Rouzier R, Rajan R, Pusztai L et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc. Natl Acad. Sci. USA102(23), 8315–8320 (2005).
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Verweij J, van der Burg ME et al. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin. Cancer Res.4, 1937–1942 (1998).
   Google Scholar
• Szebeni J. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. Crit. Rev. Ther. Drug Carrier Syst.18(6), 567–606 (2001).
   PubMed Web of Science ®Google Scholar
• Sahenk Z, Barohn R, New P et al. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch. Neurol.51, 726–729 (1994).
   PubMed Web of Science ®Google Scholar
• Authier N, Gillet JP, Fialip J et al. Description of a short-term Taxol-induced nociceptive neuropathy in rats. Brain Res.887, 239–249 (2000).
   PubMed Web of Science ®Google Scholar
• Hofle G, Bedorf N, Gerth K, Reichenbach H. Epothilone, deren Herstellungsverfahren so wie sie enthaltende Mittel, German patent disclosure DE 4138042, May 5 (1993).
   Google Scholar
• Hofle G, Bedorf N, Steinmetz H et al. Epothilone A and B-novel 16-membered macrolides with cytotoxid activity. Chem. Int. Ed. Engl.35, 1567–1569 (1996).
   Web of Science ®Google Scholar
• Mani S, Macapinlac M Jr, Goel S et al. The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs15, 553–558 (2004).
   PubMed Web of Science ®Google Scholar
• Gerth K, Bedorf N, Höfle G et al. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J. Antibiot. (Tokyo)49(6), 560–563 (1996).
   PubMed Web of Science ®Google Scholar
• Bollag DM, McQueney PA, Zhu J et al. Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action. Cancer Res.55, 2325–2333 (1995).
   PubMed Web of Science ®Google Scholar
• Kar S, Fan J, Smith MJ et al. Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J.22, 70–77 (2003).
   PubMed Web of Science ®Google Scholar
• Nettles JH, Li H, Cornett B et al. The binding mode of epothilone A on a, β-tubulin by electron crystallography. Science305, 866–869 (2004).
   PubMed Web of Science ®Google Scholar
• Altmann KH, Wartmann M, O’Reilly T et al. Epothilones and related structures: a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim. Biophys. Acta1470, M79–M91 (2000).
   PubMed Web of Science ®Google Scholar
• Giannakakou P, Sackett DL, Kang YK et al. Paclitaxel-resistant human ovarian cancer cells have mutant L-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem.272, 17118–17125 (1997).
   PubMed Web of Science ®Google Scholar
• Kowalski RJ, Ter Haar E, Longlay RE et al. Comparison of novel polymerizing agents, discodermolide and eppothilone A/B, with Taxol. Mol. Biol. Cell6, 2137 (1995).
   Google Scholar
• Lee FY, Borzilleri R, Fairchild CR et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res.7(5), 1429–1437 (2001).
   PubMed Web of Science ®Google Scholar
• Lee FY, Castenada S, Hawken D et al. Bevacizumab/ixabepilone (BMS-247550) combination produces synergistic antitumor efficacy in multiple tumor models in vivo and is superior to bevacizumab/paclitaxel combination. Presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications. PA, USA, 14–18 November (2005).
   Google Scholar
• Lee FY, Castenada S, Inigo I et al. Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2-dependent breast cancers and is accompanied by modulation of molecular response markers. J. Clin. Oncol.23(s16), 561 (2005).
   Google Scholar
• Lee FY, Camuso S, Castenada S et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. J. Clin. Oncol.24(18S), 12017 (2006).
   Google Scholar
• Nicolaou KC, Winssinger N, Pastor J et al. Synthesis of epothilones A and B in solid and solution phase. Nature387, 268–272 (1997).
   PubMed Web of Science ®Google Scholar
• Chou TC, Zhang XG, Balog A et al. Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc. Natl Acad. Sci. USA95, 9642–9647 (1998).
   PubMed Web of Science ®Google Scholar
• Altmann KH, Wartmann M, O’Reilly T. Epothilones and related structures–a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim. Biophys. Acta1470, M79–M91 (2000).
   PubMed Web of Science ®Google Scholar
• Chou TC, O’Connor OA, Tong WP et al. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc. Natl Acad. Sci. USA98, 8113–8118 (2001).
   PubMed Web of Science ®Google Scholar
• Kamath AV, Chang M, Lee FY et al. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog. Cancer Chemother. Pharmacol.56(2), 145–153 (2005).
   PubMed Web of Science ®Google Scholar
• Chuang E, Vahdat L, Caputo T et al. Phase I clinical trial of ixabepilone and pegylated liposomal doxorubicin in patients with advanced breast or ovarian cancers: New York Cancer Consortium Trial P7229. J. Clin. Oncol.25(18S) (2007) (Abstract 2570).
   Google Scholar
• Plummer R, Molife R, Verrill M et al. Phase I and pharmacokinetic study of BMS-247550 in combination with carboplatin in patients with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol.21, 2125a (2002).
   Google Scholar
• Thomas E, Bunnell CA, Vahdat LT et al. A Phase I trial of BMS-247550 in combination with capecitabine in patients with metastatic breast cancer previously treated with a taxane and an anthracycline. Proc. San Antonio Breast Cancer Symp.82, 350a (2003).
   Google Scholar
• Anderson S, Dizon D, Sabbatini P et al. Phase I trial of BMS-247550 and gemcitabine in patients with advanced solid tumor malignancies. Proc. Am. Soc. Clin. Oncol.23, 2098a (2004).
   Google Scholar
• Tripathi R, Gadgeel SM, Wozniak AJ et al. Phase I clinical trial of BMS-247550 (epothilone B derivative) in adult patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol.21, 102a (2002).
   Google Scholar
• Roché HH, Zambetti M, Dalenc F et al. Phase Ib study of ixabepilone (I) in combination with epirubicin (E) in women with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol.20, 1058 (2008).
   Google Scholar
• Damle BD, Letrent S, Duncan G et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of BMS-247550, an epothilone analog, in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol.20, 68a (2001).
   Google Scholar
• McDaid HM, Mani S, Shen H-J et al. Validation of the pharmacodynamics of BMS-247550, an analog of epothilone B, during a Phase I clinical study. Clin. Cancer Res.8, 2035–2043 (2002).
   PubMed Web of Science ®Google Scholar
• Abraham J, Agrawal M, Bakke S et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J. Clin. Oncol.21, 1866–1873 (2003).
   PubMed Web of Science ®Google Scholar
• Hao D, Hammond LA, DeBono JS et al. Continuous weekly administration of the epothilone-B derivative, BMS-247550 (NSC 10428): a Phase I and pharmacokinetic study. Proc. Am. Soc. Clin. Oncol.21, 103a (2002).
   Google Scholar
• Spriggs D, Soignet S, Bienvenu B et al. Phase 1 first-in-man study of epothilone B analog BMS-247550 in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol.20, 428a (2001).
   Google Scholar
• Gadgeel SM, Wozniak A, Boinpally RR et al. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin. Cancer Res.11, 6233–6239 (2005).
   PubMed Web of Science ®Google Scholar
• Mani S, McDaid H, Hamilton A et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin. Cancer Res.10, 1289–1298 (2004).
   PubMed Web of Science ®Google Scholar
• Shimizu T, Yamamoto N, Fujisaka Y et al. Phase I study of BMS-247550 (Ixabepilone) given every 3 weeks in Japanese patients with refractory solid tumors. Proc. Am. Soc. Clin. Oncol.24, 2050a (2005).
   Google Scholar
• Low JA, Wedam SB, Lee JJ et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J. Clin. Oncol.23(12), 2726–2734 (2005).
   PubMed Web of Science ®Google Scholar
• Denduluri N, Lee JJ, Walshe J et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest. New Drugs25(1), 63–67 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas E, Tabernero J, Fornier M et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J. Clin. Oncol.25(23), 3399–3406 (2007).
   PubMed Web of Science ®Google Scholar
• Roche H, Yelle L, Cognetti F et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J. Clin. Oncol.25(23), 3415–3420 (2007).
   PubMed Web of Science ®Google Scholar
• Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol.25(23), 3407–3414 (2007).
   PubMed Web of Science ®Google Scholar
• Denduluri N, Low JA, Lee JJ et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J. Clin. Oncol.25(23), 3421–3427 (2007).
   PubMed Web of Science ®Google Scholar
• Baselga J, Gianni L, Llombart A et al. Predicting response to ixabepilone: genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC). Breast Cancer Res. Treat.96(Suppl. 1), (2005) (Abstract 305).
   Google Scholar
• Sataloff DM, Mason BA, Prestipino AJ et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J. Am. Coll. Surg.180(3), 297–306 (1995).
   PubMed Web of Science ®Google Scholar
• Bunnell CA, Klimovsky J, Thomas E et al. Final efficacy results of a Phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline. Proc. Am. Soc. Clin. Oncol.24, 10511 (2006).
   Google Scholar
• Moulder SL, Wang M, Gradishar W et al. A Phase II trial of trastuzumab, weekly ixabepilone and carboplatin (TIC) in patients with HER2/neu-positive (HER2+) metastatic breast cancer (MBC): A trial coordinated by the Eastern Cooperative Oncology Group (E2103). Breast Cancer Res. Treat.106(Suppl. 1) (2007) (Abstract 152).
   Google Scholar
• Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med.357(26), 2666–2676 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol.20, 25(33), 5210–5217 (2007).
   Google Scholar
• Rubin EH, Rothermel J, Tesfaye F et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J. Clin. Oncol.23, 9120–9129 (2005).
   PubMed Web of Science ®Google Scholar
• Calvert PM, O’Neill V, Twelves C et al. A Phase I study and pharmacokinetic study of EPO906 (epothilone B), given every three weeks, in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol.20, 429a (2001).
   Google Scholar
• Blum W, Aichholz R, Ramstein P et al. In vivo metabolism of epothilone B in tumor-bearing nude mice: identification of three new epothilone B metabolites by capillary high-pressure liquid chromatography/mass spectrometry/tandem mass spectrometry. Rapid Commun. Mass Spectrom.15, 41–49 (2001).
   PubMed Web of Science ®Google Scholar
• Aisner J, Gore M, Rubin EH et al. Two Phase IB trials of EPO906 plus carboplatin in patients with malignancies. Proc. Am. Soc. Clin. Oncol.22, 143a (2003).
   Google Scholar
• Gore M, Kaye S, Oza A et al. Phase I trial of patupilone plus carboplatin in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol.24, 5087a (2005).
   Google Scholar
• Dumez H, Van Oosterom AT, Rothermel JD et al. Phase Ib/II dose-escalation trial evaluating the safety and tolerability of EPO906 plus capecitabine in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol.23, 2093a (2004).
   Google Scholar
• Rinehart JJ, Rothermel JD, Anderson P et al. Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus gemcitabine in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol.24, 3100a (2005).
   Google Scholar
• Abrey L, Wen PY, Govindan R et al. Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): an open-label, multicenter, Phase II study. Proc. Am. Soc. Clin. Oncol.25, 18058 (2007).
   Google Scholar
• Piro LD, Rosen LS, Parson M et al. KOS-862 (epothilone D). A comparison of two schedules in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol.22 (2003) (Abstract 539).
   Google Scholar
• Spriggs DR, Dupont J, Pezzulli S et al. KOS-862 (Epothilone D): Phase 1 dose escalating and pharmacokinetic (PK) study in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol.22 (2003) (Abstract 894).
   Google Scholar
• Holen KD, Syed S, Hannah AL et al. Phase I study using continuous intravenous (CI) KOS-862 (epothilone D) in patients with solid tumors. J. Clin. Oncol.22(14S) (2004) (Abstract 2024).
   Google Scholar
• Buzdar A, Silverman P, Kaufman PA et al. A Phase II study of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer: updated results. Breast Cancer Res. Treat.94(Suppl. 1) (2005) (Abstract 1087).
   Google Scholar
• Marshall JL, Ramalingam S, Hwang J et al. Phase 1 and pharmacokinetic (PK) study of weekly KOS-862 (epothilone D) combined with gemcitabine (GEM) in patients (Pts) with advanced solid tumors. Proc. Am. Soc. Clin. Oncol.24, 2041a (2005).
   Google Scholar
• Monk JP, Calero-Villalona M, Dupont J et al. Phase 1 trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors. Proc. Am. Soc. Clin. Oncol.24, 2049 (2005).
   Google Scholar
• Cortes J, Climent MA, Gomez P et al. A Phase I trial of weekly combination KOS-862 (Epothilone D) and trastuzumab in HER-2 overexpressing malignancies. J. Clin. Oncol.24(18S) (2006) (Abstract 2028).
   Google Scholar
• Villalona-Calero M, Goel S, Schaaf L et al. First-in-human Phase I trial of a novel epothilone, KOS-1584. J. Clin. Oncol.24, 2003a (2006).
   Web of Science ®Google Scholar
• Stopeck A, Moulder S, Jones S et al. Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules. Proc. Am. Soc. Clin. Oncol.25, 2571 (2007).
   Google Scholar
• Hoffmann J, Winsel S, Hammer S et al. Activity of the third-generation epothilone ZK-EPO, compared with paclitaxel and other tubulin-binding agents, in the inhibition of breast tumor cell growth and proliferation. Breast Cancer Res. Treat.100(Suppl. 1) (2006) (Abstract 1013).
   Google Scholar
• Schmid P, Kiewe P, Kuehnhardt D et al. A Phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol.23(16S) (2006) (Abstract 2051).
   Google Scholar
• Sessa C, Perotti A, Llado A et al. Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Ann. Oncol.18(9), 1548–1553 (2007).
   PubMed Web of Science ®Google Scholar
• Valero V, Jones SE, Von Hoff DD et al. A Phase II study of docetaxel in patients with paclitaxel resistant metastatic breast cancer. J. Clin. Oncol.16, 3362–3368 (1998).
   PubMed Web of Science ®Google Scholar
• Green MC, Buzdar AU, Smith T et al. Weekly paclitaxel improves pathological complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J. Clin. Oncol.23, 5983–5991 (2005).
   PubMed Web of Science ®Google Scholar
• Pusztai L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann. Oncol.18(12), 1215–1220 (2007).
   Google Scholar
• Ayers M, Symmans WF, Stec J et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. J. Clin. Oncol.22, 2267–2269 (2004).
   Google Scholar
• Awada A, Bleiberg H, de Valeriola D et al. Phase I clinical and pharmacology study of the epothilone analog BMS-247550 given weekly in patients (pts) with advanced solid tumors. Proc. Am. Soc. Clin. Oncol.20, 427a (2001).
   Google Scholar
• Burris HA III, Awada A, Jones S et al. Phase I study of the novel epothilone BMS-247550 administered weekly in patients (pts) with advanced malignancies. Proc. Am. Soc. Clin. Oncol.21, 412a (2002).
   Google Scholar
• Zhuang SH, Agrawal M, Edgerly M et al. A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer103, 1932–1938 (2005).
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Burris HA III, Jones S et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J. Clin. Oncol.25(9), 1082–1088 (2007).
   PubMed Web of Science ®Google Scholar